Mr. Ron Nagar reports

TEMPRAMED RECEIVES POSITIVE RESPONSE ON PAYOR REIMBURSEMENT MODEL DRIVING SIGNIFICANT RETURN ON INVESTMENT FOR MEDICAL PAYOR COVERAGE

Tempramed Technologies Ltd. has received independent validation of its payer return-on-investment (ROI) model from the Validation Institute, a leading authority in health care economic credibility in the United States. The Validation Institute provided a positive response on the company's payer reimbursement strategy, which is a significant step toward receiving coverage for its product portfolio.

Highlights:

• ROI model validated for savings and metrics by Validation Institute, a leading authority in health care value and economic credibility;
• Confirms that payers covering Vivi Cap can achieve meaningful cost savings and return on investment;
• Supports Tempramed's planned payer pilot programs aimed at confirming savings and securing reimbursement coverage;
• Establishes a scalable, reimbursement-driven growth pathway with significant upside potential for investors.

The validated model demonstrates that use of Vivi Cap and Vivi Epi by patients prescribed temperature-sensitive injectable medications -- such as insulin, GLP-1 therapies, biologics and epinephrine -- can generate significant net cost savings for health care payers. These savings are driven by reduced medication waste, fewer adverse clinical events, improved adherence and lower anxiety-related health care utilization.

The Validation Institute reviewed Tempramed's savings methodology, assumptions and calculations and confirmed that the model meets or exceeds industry standards for health care economic analysis. The validation is effective through January, 2027, and includes a formal credibility guarantee for the savings methodology.

Building on this independent validation, Tempramed is now advancing discussions with U.S. health care payers that the Validation Institute will introduce through its established purchaser network. The objective of these discussions is to initiate pilot programs for covered patient populations, enabling payers to confirm real-world savings outcomes and accelerate decisions around coverage and reimbursement for Vivi Cap and Vivi Epi.

These pilots are expected to serve as a catalyst for broader adoption across national and regional health plans, employer-sponsored plans and value-based integrated care organizations.

"This validation represents a major inflection point for Tempramed and is a meaningful step in the right direction in our reimbursement strategy to begin receiving payer coverage from major U.S. payers and others for our products," said Ron Nagar, chief executive officer of Tempramed. "For the first time, we have independent, third party confirmation that Vivi Cap is not only meaningful for patients -- but also economically compelling for payers. This fundamentally changes the scale of the opportunity in front of us."

"Our discussions with payers are now grounded in validated economics, not assumptions," Mr. Nagar continued. "When a low-cost, reusable device can prevent medication degradation, reduce emergency events and deliver rapid payback within months, reimbursement becomes a logical next step. Successful pilot programs can unlock recurring, high-volume demand and position Tempramed as a standard-of-care solution across multiple chronic disease categories."

Daniel Salomon, Tempramed's general manager in the United States, added: "These pilot programs are a pathway to demonstrate real-world reductions in drug waste, avoidable medical events and total cost of care across high-cost injectable categories such as insulin, GLP-1s, biologics and emergency therapies. In addition, we believe success of this front will also strengthen our partnerships with pharmaceutical manufacturers focused on patient support, adherence and life-cycle value."

Al Lewis, founder and validator-in-chief of the Validation Institute, commented: "Health care buyers are increasingly demanding proof, not promises. Tempramed's Vivi Cap ROI model meets our standards for credible, transparent savings analysis. The economics demonstrate that payers covering this device can achieve rapid return on investment while improving outcomes for patients using temperature-sensitive medications."

About Tempramed Technologies Ltd.

Tempramed Technologies is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, FDA-registered (U.S. Food and Drug Administration), space-grade thermal insulation devices that work 24 hours a day, seven days a week without batteries or external power. With a proven product line, including Vivi Cap and Vivi Epi, and a smart technology platform on the horizon, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed is advancing the future of medication protection and adherence.

We seek Safe Harbor.